In another blow to Allergan’s efforts to retain exclusivity for its dry-eye drug Restasis, the U.S. Patent Trials and Appeals Board said Allergan’s transfer of the patents to the St. Regis Mohawk tribe last year conferred only “illusory rights” and denied the company’s motion to terminate Mylan’s challenge to six of its patents.
Source: Drug Industry Daily